ADC THERAPEUTICS (UK) LIMITED
Get an alert when ADC THERAPEUTICS (UK) LIMITED files next
Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.
Next accounts due
2026-09-30 (in 4mo)
Last filed for 2024-12-31
Confirmation statement due
2026-12-26 (in 7mo)
Last made up 2025-12-12
Watchouts
None on the register
Cash
£4M
+5.7% vs 2023
Net assets
£11M
+17.1% vs 2023
Employees
57
-17.4% vs 2023
Profit before tax
£2M
+263.9% vs 2023
Net assets
2-year trend · vs Health Care median
Accounts
2-year trend · latest reflected 2024-12-31
| Metric | Trend | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Turnover | £14,548,911 | £14,449,618 | |
| Operating profit | £807,081 | £1,998,426 | |
| Profit before tax | £455,022 | £1,656,025 | |
| Net profit | £333,521 | £1,238,252 | |
| Cash | £4,078,851 | £4,312,553 | |
| Total assets less current liabilities | £15,633,749 | £16,309,429 | |
| Net assets | £9,181,720 | £10,749,998 | |
| Equity | £9,181,720 | £10,749,998 | |
| Average employees | 69 | 57 | |
| Wages | £5,663,192 | £5,844,800 |
Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers
Ratios
Computed from the line items above — sparklines read oldest → newest
| Ratio | Trend | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating margin | 5.5% | 13.8% | |
| Net margin | 2.3% | 8.6% | |
| Return on capital employed | 5.2% | 12.3% | |
| Gearing (liabilities / total assets) | 51.6% | 47.1% | |
| Current ratio | 1.85x | 2.22x | |
| Interest cover | 2.20x | 5.89x |
Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.
Audit & accounting basis
- Accounting basis
- FRS 101
- Reporting scope
- Standalone (parent only)
- Auditor
- Sopher + Co LLP
- Audit opinion
- Unqualified (clean)
- Going concern
- Affirmed
“The parent has provided a letter of support to ensure the Company has adequate financial resources and cash available to continue to operate for a period of at least 12 months after approval of the financial statements. The directors have obtained confirmation that the transfer arrangements with the wider ADC Therapeutics group will continue over the going concern period, and the directors are satisfied that the group has sufficient liquidity to support the company taking into account both the budgeted and downside scenarios. Based on the Company's financial position and the letter of support, the directors have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. Accordingly, they continue to adopt the going concern basis of accounting in preparing the annual report and financial statements.”
Significant events
- “On June 11, 2025, the Board of Directors of ADC Therapeutics SA the parent company, approved a strategic reprioritization and restructuring plan pursuant to which the Company plans to shut down its UK facility and reduce the global workforce of ADCT UK by approximately 75%.”
Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers
People
3 active · 8 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| KORCAKOVA, Veronika | Secretary | 2020-08-10 | — | — |
| GRAHAM, Peter James | Director | 2023-10-01 | May 1966 | American |
| KALLEBO, Lisa Michelle | Director | 2023-10-01 | Apr 1975 | American |
Show 8 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| GONCALVES, Dulce | Secretary | 2015-01-22 | 2020-08-01 |
| THROGMORTON SECRETARIES LLP | Corporate Secretary | 2015-01-22 | 2019-07-08 |
| CORR, Peter Bartley | Director | 2014-12-12 | 2020-08-10 |
| EVANS-FREKE, Stephen Ralfe | Director | 2014-12-12 | 2020-08-10 |
| FORER, Michael | Director | 2014-12-12 | 2023-10-01 |
| SKELTON, Lisa | Director | 2020-08-10 | 2026-01-01 |
| VAN BERKEL, Patrick | Director | 2020-08-10 | 2026-01-01 |
| WARD, John Barrie, Dr | Director | 2015-03-12 | 2020-08-10 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Adc Therapeutics Sa | Corporate entity | Shares 75–100%, Voting 75–100%, Appoints directors | 2020-05-14 | Active |
| Mr Stephen Ralfe Evans-Freke | Individual | Shares 25–50% | 2016-04-06 | Ceased 2020-05-14 |
| Mr Peter Bartley Corr | Individual | Shares 25–50% | 2016-04-06 | Ceased 2020-05-14 |
Filing timeline
Last 20 of 61 total filings
| Date | Type | Category | Description | |
|---|---|---|---|---|
| 2026-01-06 | TM01 | officers | Termination director company with name termination date | |
| 2026-01-06 | TM01 | officers | Termination director company with name termination date | |
| 2025-12-30 | AA | accounts | Accounts with accounts type full | |
| 2025-12-19 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2024-12-20 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2024-09-26 | AA | accounts | Accounts with accounts type full | |
| 2023-12-15 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2023-11-15 | AP01 | officers | Appoint person director company with name date | |
| 2023-11-15 | AP01 | officers | Appoint person director company with name date | |
| 2023-11-15 | TM01 | officers | Termination director company with name termination date | |
| 2023-10-06 | AA | accounts | Accounts with accounts type full | |
| 2022-12-16 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2022-09-29 | AA | accounts | Accounts with accounts type full | |
| 2022-09-16 | AD01 | address | Change registered office address company with date old address new address | |
| 2022-08-30 | MR04 | mortgage | Mortgage satisfy charge full | |
| 2022-08-30 | MR04 | mortgage | Mortgage satisfy charge full | |
| 2022-08-17 | MR01 | mortgage | Mortgage create with deed with charge number charge creation date | |
| 2022-08-17 | MR01 | mortgage | Mortgage create with deed with charge number charge creation date | |
| 2022-08-17 | MR01 | mortgage | Mortgage create with deed with charge number charge creation date | |
| 2021-12-16 | CS01 | confirmation-statement | Confirmation statement with no updates |
Public-record activity
Raw counts from Companies House — last 12–24 months
- Filings
- 4
- Capital events
- 0
- Officers appointed
- 0
- Officers resigned
- 2
last 12 months
last 24 months
last 12 months
last 12 months
Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.
Year-on-year
FY2023 → FY2024 · period ending 2024-12-31 vs 2023-12-31
-
Turnover
-0.7%
£14,548,911 £14,449,618
-
Cash
+5.7%
£4,078,851 £4,312,553
-
Net assets
+17.1%
£9,181,720 £10,749,998
-
Employees
-17.4%
69 57
-
Operating profit
+147.6%
£807,081 £1,998,426
-
Profit before tax
+263.9%
£455,022 £1,656,025
-
Wages
+3.2%
£5,663,192 £5,844,800
Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers